5wnb › Citations

Structures of respiratory syncytial virus G antigen bound to broadly neutralizing antibodies.

Fedechkin SO, George NL, Wolff JT, Kauvar LM, DuBois RM
Sci Immunol 3 (2018)
Related entries: 5wn9, 5wna

Cited: 43 times
EuropePMC logo PMID: 29523582

Abstract

Respiratory syncytial virus (RSV) is a top cause of severe lower respiratory tract disease and mortality in young children and the elderly. The viral envelope G glycoprotein contributes to pathogenesis through its roles in host cell attachment and modulation of host immunity. Although the G glycoprotein is a target of protective RSV-neutralizing antibodies, its development as a vaccine antigen has been hindered by its heterogeneous glycosylation and sequence variability outside a conserved central domain (CCD). We describe the cocrystal structures of two high-affinity broadly neutralizing human monoclonal antibodies bound to the RSV G CCD. The antibodies bind to neighboring conformational epitopes, which we named antigenic sites γ1 and γ2, that span a highly conserved surface, illuminating an important region of vulnerability. We further show that isolated RSV G CCD activates the chemokine receptor CX3CR1 and that antibodies block this activity. These studies provide a template for rational vaccine design targeting this key contributor to RSV disease.

Articles - 5wnb mentioned but not cited (1)

  1. Structures of respiratory syncytial virus G antigen bound to broadly neutralizing antibodies. Fedechkin SO, George NL, Wolff JT, Kauvar LM, DuBois RM. Sci Immunol 3 eaar3534 (2018)


Reviews citing this publication (14)

  1. Fc-Mediated Antibody Effector Functions During Respiratory Syncytial Virus Infection and Disease. van Erp EA, Luytjes W, Ferwerda G, van Kasteren PB. Front Immunol 10 548 (2019)
  2. Respiratory syncytial virus entry and how to block it. Battles MB, McLellan JS. Nat Rev Microbiol 17 233-245 (2019)
  3. Role of Type I Interferon (IFN) in the Respiratory Syncytial Virus (RSV) Immune Response and Disease Severity. Hijano DR, Vu LD, Kauvar LM, Tripp RA, Polack FP, Cormier SA. Front Immunol 10 566 (2019)
  4. RSV Prevention in All Infants: Which Is the Most Preferable Strategy? Esposito S, Abu Raya B, Baraldi E, Flanagan K, Martinon Torres F, Tsolia M, Zielen S. Front Immunol 13 880368 (2022)
  5. Respiratory syncytial virus: from pathogenesis to potential therapeutic strategies. Shang Z, Tan S, Ma D. Int J Biol Sci 17 4073-4091 (2021)
  6. Functional Features of the Respiratory Syncytial Virus G Protein. Anderson LJ, Jadhao SJ, Paden CR, Tong S. Viruses 13 1214 (2021)
  7. Immune-Modulation by the Human Respiratory Syncytial Virus: Focus on Dendritic Cells. Tognarelli EI, Bueno SM, González PA. Front Immunol 10 810 (2019)
  8. Sendai Virus-Vectored Vaccines That Express Envelope Glycoproteins of Respiratory Viruses. Russell CJ, Hurwitz JL. Viruses 13 1023 (2021)
  9. Recent Progress in the Discovery and Development of Monoclonal Antibodies against Viral Infections. Mokhtary P, Pourhashem Z, Mehrizi AA, Sala C, Rappuoli R. Biomedicines 10 1861 (2022)
  10. Review and Update of Active and Passive Immunization Against Respiratory Syncytial Virus. Verwey C, Madhi SA. BioDrugs 37 295-309 (2023)
  11. All Eyes on the Prefusion-Stabilized F Construct, but Are We Missing the Potential of Alternative Targets for Respiratory Syncytial Virus Vaccine Design? Schaerlaekens S, Jacobs L, Stobbelaar K, Cos P, Delputte P. Vaccines (Basel) 12 97 (2024)
  12. Importance of Virus Characteristics in Respiratory Syncytial Virus-Induced Disease. San-Juan-Vergara H, Peeples ME. Immunol Allergy Clin North Am 39 321-334 (2019)
  13. New Developments and Challenges in Antibody-Based Therapies for the Respiratory Syncytial Virus. Diethelm-Varela B, Soto JA, Riedel CA, Bueno SM, Kalergis AM. Infect Drug Resist 16 2061-2074 (2023)
  14. Structural basis for respiratory syncytial virus and human metapneumovirus neutralization. Miller RJ, Mousa JJ. Curr Opin Virol 61 101337 (2023)

Articles citing this publication (28)

  1. RSV disease in infants and young children: Can we see a brighter future? Baraldi E, Checcucci Lisi G, Costantino C, Heinrichs JH, Manzoni P, Riccò M, Roberts M, Vassilouthis N. Hum Vaccin Immunother 18 2079322 (2022)
  2. Protective antigenic sites in respiratory syncytial virus G attachment protein outside the central conserved and cysteine noose domains. Lee J, Klenow L, Coyle EM, Golding H, Khurana S. PLoS Pathog 14 e1007262 (2018)
  3. Effects of Alterations to the CX3C Motif and Secreted Form of Human Respiratory Syncytial Virus (RSV) G Protein on Immune Responses to a Parainfluenza Virus Vector Expressing the RSV G Protein. Liang B, Kabatova B, Kabat J, Dorward DW, Liu X, Surman S, Liu X, Moseman AP, Buchholz UJ, Collins PL, Munir S. J Virol 93 e02043-18 (2019)
  4. Conformational Flexibility in Respiratory Syncytial Virus G Neutralizing Epitopes. Fedechkin SO, George NL, Nuñez Castrejon AM, Dillen JR, Kauvar LM, DuBois RM. J Virol 94 e01879-19 (2020)
  5. Distinct patterns of within-host virus populations between two subgroups of human respiratory syncytial virus. Lin GL, Drysdale SB, Snape MD, O'Connor D, Brown A, MacIntyre-Cockett G, Mellado-Gomez E, de Cesare M, Bonsall D, Ansari MA, Öner D, Aerssens J, Butler C, Bont L, Openshaw P, Martinón-Torres F, Nair H, Bowden R, RESCEU Investigators, Golubchik T, Pollard AJ. Nat Commun 12 5125 (2021)
  6. Respiratory Syncytial Virus (RSV) G Protein Vaccines With Central Conserved Domain Mutations Induce CX3C-CX3CR1 Blocking Antibodies. Bergeron HC, Murray J, Nuñez Castrejon AM, DuBois RM, Tripp RA. Viruses 13 352 (2021)
  7. Evolution of respiratory syncytial virus genotype BA in Kilifi, Kenya, 15 years on. Kamau E, Otieno JR, Lewa CS, Mwema A, Murunga N, Nokes DJ, Agoti CN. Sci Rep 10 21176 (2020)
  8. Antibody and Local Cytokine Response to Respiratory Syncytial Virus Infection in Community-Dwelling Older Adults. Yu X, Lakerveld AJ, Imholz S, Hendriks M, Ten Brink SCA, Mulder HL, de Haan K, Schepp RM, Luytjes W, de Jong MD, van Beek J, van Kasteren PB. mSphere 5 e00577-20 (2020)
  9. Combinatorial F-G Immunogens as Nipah and Respiratory Syncytial Virus Vaccine Candidates. Isaacs A, Cheung STM, Thakur N, Jaberolansar N, Young A, Modhiran N, Bailey D, Graham SP, Young PR, Chappell KJ, Watterson D. Viruses 13 1942 (2021)
  10. Dominance of the ON1 Genotype of RSV-A and BA9 Genotype of RSV-B in Respiratory Cases from Jeddah, Saudi Arabia. A Al-Sharif H, El-Kafrawy SA, Yousef JM, Kumosani TA, Kamal MA, Khathlan NA, Kaki RM, Alnajjar AA, Azhar EI. Genes (Basel) 11 E1323 (2020)
  11. Structure-Based Design and Antigenic Validation of Respiratory Syncytial Virus G Immunogens. Nuñez Castrejon AM, O'Rourke SM, Kauvar LM, DuBois RM. J Virol 96 e0220121 (2022)
  12. Analysis of circulating respiratory syncytial virus A strains in Shanghai, China identified a new and increasingly prevalent lineage within the dominant ON1 genotype. Zhao X, Wang C, Jiang H, Zhang H, Fang F, Chen M, Yuan Z, Teng Z, Liu J, Zhang X. Front Microbiol 13 966235 (2022)
  13. Anti-G protein antibodies targeting the RSV G protein CX3C chemokine region improve the interferon response. Bergeron HC, Kauvar LM, Tripp RA. Ther Adv Infect Dis 10 20499361231161157 (2023)
  14. Ephedrae Herba and Cinnamomi Cortex interactions with G glycoprotein inhibit respiratory syncytial virus infectivity. Fujikane A, Sakamoto A, Fujikane R, Nishi A, Ishino Y, Hiromatsu K, Nabeshima S. Commun Biol 5 94 (2022)
  15. A morphological transformation in respiratory syncytial virus leads to enhanced complement deposition. Kuppan JP, Mitrovich MD, Vahey MD. Elife 10 e70575 (2021)
  16. Evolutionary dynamics of group A and B respiratory syncytial virus in China, 2009-2018. Ma Y, Jiang H, Wan Z, Li S, Li Y, Wang W, Jin X, Li Y, Zhang C. Arch Virol 166 2407-2418 (2021)
  17. Development of Luciferase Immunoprecipitation Systems (LIPS) Assay to Detect IgG Antibodies against Human Respiratory Syncytial Virus G-Glycoprotein. Crim RL, Kumari S, Jayanti P, Audet S, Kulkarni A, Beeler J. Vaccines (Basel) 7 E16 (2019)
  18. Non-glycosylated G protein with CpG ODN provides robust protection against respiratory syncytial virus without inducing eosinophilia. Kawahara E, Shibata T, Hirai T, Yoshioka Y. Front Immunol 14 1282016 (2023)
  19. RSV pre-fusion F protein enhances the G protein antibody and anti-infectious responses. Su C, Zhong Y, Zhao G, Hou J, Zhang S, Wang B. NPJ Vaccines 7 168 (2022)
  20. Transmission of Respiratory Syncytial Virus genotypes in Cali, Colombia. Londono-Avendano MA, Peláez-Moreno M, López Medina E, Moreno Turriago MS, Parra Patiño B. Influenza Other Respir Viruses 15 521-528 (2021)
  21. A human antibody potently neutralizes RSV by targeting the conserved hydrophobic region of prefusion F. Yi C, Su C, Sun X, Lu X, Si C, Liu C, Yang Z, Yuan H, Huang Y, Wen J, He Y, Zhang Y, Ma L, Cong Y, Zhao G, Ling Z, Wang B, Sun B. Sci China Life Sci 66 729-742 (2023)
  22. An Automated Strategy to Handle Antigenic Variability in Immunisation Protocols, Part II: In Vitro Transcribed mRNA Vector Design for Inoculation Against Infectious Agent Variants. Pereira GC. Methods Mol Biol 2575 323-340 (2023)
  23. Design and Preclinical Evaluation of a Nanoparticle Vaccine against Respiratory Syncytial Virus Based on the Attachment Protein G. Voorzaat R, Cox F, van Overveld D, Le L, Tettero L, Vaneman J, Bakkers MJG, Langedijk JPM. Vaccines (Basel) 12 294 (2024)
  24. Computational Insights into the Interaction of the Conserved Cysteine-Noose Domain of the Human Respiratory Syncytial Virus G Protein with the Canonical Fractalkine Binding site of Transmembrane Receptor CX3CR1 Isoforms. Piloto JV, Dias RVR, Mazucato WSA, Fossey MA, de Melo FA, Almeida FCL, de Souza FP, Caruso IP. Membranes (Basel) 14 84 (2024)
  25. Immune Prophylaxis Targeting the Respiratory Syncytial Virus (RSV) G Protein. Bergeron HC, Murray J, Arora A, Nuñez Castrejon AM, DuBois RM, Anderson LJ, Kauvar LM, Tripp RA. Viruses 15 1067 (2023)
  26. Immune Responses and Protection Profiles in Mice Induced by Subunit Vaccine Candidates Based on the Extracellular Domain Antigen of Respiratory Syncytial Virus G Protein Combined with Different Adjuvants. Han R, Wang T, Cheng X, Bing J, Li J, Deng Y, Shan X, Zhang X, Wang D, Sun S, Tan W. Vaccines (Basel) 12 686 (2024)
  27. Immunogenicity and protective efficacy of an RSV G S177Q central conserved domain nanoparticle vaccine. Bergeron HC, Murray J, Juarez MG, Nangle SJ, DuBois RM, Tripp RA. Front Immunol 14 1215323 (2023)
  28. KD-409, a Respiratory Syncytial Virus FG Chimeric Protein without the CX3C Chemokine Motif, Is an Efficient Respiratory Syncytial Virus Vaccine Preparation for Passive and Active Immunization in Mice. Yamaue R, Torikai M, Terashima M, Mori H. Vaccines (Basel) 12 753 (2024)


Quick links